Patents Assigned to Office of Technology Transfer
-
Patent number: 11959096Abstract: Provided herein are methods of reducing or eliminating undifferentiated pluripotent stem cells, where the methods comprise contacting an effective amount of a compound to a heterogeneous cell population or sample comprising or suspected of comprising differentiated cell types and undifferentiated pluripotent stem cells, whereby the contacting selectively reduces or eliminates undifferentiated pluripotent stem cells from the cell population or sample. Also provided are methods for obtaining a population of stem cell-derived cell types substantially free of undifferentiated pluripotent stem cells as well as isolated populations of such of stem cell-derived cell types.Type: GrantFiled: September 18, 2020Date of Patent: April 16, 2024Assignees: The Medical College of Wisconsin, Inc., The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services NIH, Office of Technology TransferInventors: Rebekah L. Gundry, Kenneth R. Boheler, Erin M. Kropp
-
Patent number: 11627907Abstract: An intracellular monitoring device (IMD) that fits completely inside a living cell, and causes no significant impairment, to a cell's normal biological processes. The IMD monitors a cell for its level of a biological substance (e.g., calcium ion concentration) of interest. If the biological substance reaches or exceeds a threshold, the IMD transmits an electromagnetic signal, received by an antenna outside the cell. Each IMD has its electromagnetic signal encoded with a unique frequency. Detection of the frequency components, in the signals received by an antenna, permits identification of the source IMD's. A high calcium ion concentration is indicative of a strongly-activated cerebral cortex neuron. Brain tissue is relatively transparent to near infrared, making it a good frequency band, for the electromagnetic signals from neuron-monitoring IMD's. The near infrared of each IMD can be produced by quantum dots, powered by bioelectric catalysis triggered by high calcium ion concentration.Type: GrantFiled: June 24, 2019Date of Patent: April 18, 2023Assignees: National Institutes of Health, Office of Technology Transfer, Galiana Technology Inc.Inventors: Bruce T Hope, Mark A Wells, Gregory D Sutton
-
Patent number: 11505559Abstract: The disclosure provides compounds of Formula I, which may be useful as aldehyde dehydrogenase inhibitors and the pharmaceutically acceptable salts thereof. The variables, J, R4, G, Q, and ring A are defined herein. Aldehyde dehydrogenase inhibitors of Formula I are useful for treating a variety of conditions including cancer and inflammation. The disclosure includes methods for using compounds and salts of Formula I to treat colon cancer, pancreatic cancer, nasopharyngeal carcinoma, thyroid cancer, prostate cancer, ovarian cancer, head and neck squamous cell carcinoma, lung cancer, hepatocellular carcinoma, leukemia, brain tumors breast cancer, atherosclerosis, ischaemic heart disease, acne vulgaris, asthma, autoimmune diseases, autoinflammatory diseases, chronic prostatitis, glomerulonephritis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, rheumatoid arthritis, sarcoidosis, transplant rejection, vasculitis, and interstitial cystitis.Type: GrantFiled: October 30, 2018Date of Patent: November 22, 2022Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH, YALE UNIVERSITYInventors: Shyh Ming Yang, David J. Maloney, Natalia Martinez, Adam Yasgar, Anton Simeonov, Vasilis Vasiliou
-
Patent number: 11351185Abstract: A pharmaceutical composition containing any one or more of 4?-O-isolvalerylspiramycin I, II and III counters tumorigenesis and reduces or prevents metastasis by inhibiting selenoprotein H to trigger genomic instability and cell-cycle arrest in cancer cells.Type: GrantFiled: March 11, 2020Date of Patent: June 7, 2022Assignees: ASCLEA CORPORATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTHInventors: Enhong Jiang, Zhengping Zhuang, Jing Cui
-
Patent number: 11129835Abstract: The invention features compositions and methods for inhibiting the Pin1 protein, and the treatment of disorders characterized by elevated Pin1 levels.Type: GrantFiled: September 13, 2019Date of Patent: September 28, 2021Assignees: Beth Israel Deaconess Medical Center, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services Office of Technology Transfer, National Institutes of HealthInventors: Kun Ping Lu, Matthew Brian Boxer, Mindy Irene Emily Davis, Rajan Pragani, Min Shen, Anton Momtchilov Simeonov, Shuo Wei, Xiao Zhen Zhou
-
Patent number: 10935542Abstract: Variations in the differentiation and lineage potential of stem cells, including mesenchymal stem cells, currently limit their therapeutic use. The ability to identify, isolate, and specifically amplify stem cell populations with desired differentiation potential would contribute the use of stem cells in research and therapy. The present invention discloses a method of assessing differentiation potential of stem cells by measuring the differential expression of antigens CD 146 and NG2 on the stem cells. The correlation between CD 146 and NG2 expression and differentiation and trilineage potential is explored. The invention also discloses methods to specifically amplify or enrich stem cells with desired differentiation potential, monitor the differentiation potential of a heterogeneous stem cell population, quantify the heterogeneity in differentiation potential of a stem cell culture, and remove stem cells with specific differentiation potentials from a heterogeneous cell culture.Type: GrantFiled: December 21, 2011Date of Patent: March 2, 2021Assignee: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND OFFICE OF TECHNOLOGY TRANSFER AND INTELLECTUAL PROPERTY DEVELOPMENTInventors: Kim O'Connor, Katie Russell
-
Patent number: 10912797Abstract: Genetically modified compositions, such as non-viral vectors and tumor infiltrating lymphocytes, for the treatment of gastrointestinal cancer are disclosed. Disclosed are methods of utilizing a CRISPR system to generate genetically modified compositions. Also disclosed are the methods of making and using the genetically modified compositions for the treatment of gastrointestinal cancer.Type: GrantFiled: April 6, 2018Date of Patent: February 9, 2021Assignees: INTIMA BIOSCIENCE, INC., REGENTS OF THE UNIVERSITY OF MINNESOTA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTHInventors: Branden Moriarity, Beau Webber, Modassir Choudhry, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo
-
Patent number: 10670610Abstract: Disclosed are specific biomarkers that allow for early testing of preeclampsia/HELLP syndrome. Thus, a method is provided predicting preeclampsia in a pregnant woman. Also disclosed is a kit comprising means for assaying a sample from a pregnant woman for the concentrations of the specific biomarkers.Type: GrantFiled: June 13, 2013Date of Patent: June 2, 2020Assignees: Wayne State University, The United States of America as represented by The Secretary, Department of Health and Human Services Office of Technology Transfer, National Institutes of Health, Semmelweis University, Genesis Theranostix Korlatolt Felelossegu TarsasagInventors: Adi L. Tarca, Nandor Than, Gabor Juhasz, Adrienna Katalin Kekesi, Hamutal Meiri, Zoltan Papp, Roberto Romero
-
Patent number: 10273291Abstract: Antibody VRC01 represents a human immunoglobulin that neutralizes—˜90% of diverse HIV-1 isolates. To understand how such broadly neutralizing HIV-1 antibodies develop and recognize the viral envelope, we used X-ray crystallography and 454 pyrosequencing to characterize additional antibodies from HIV-1-infected individuals. Crystal structures revealed a convergent mode of binding of different antibodies to the same CD4-binding-site epitope. Antibody recognition was achieved through the evolution of complementary contact domains that were generated in diverse ways. Phylogenetic analysis of expressed heavy and light chains determined by deep sequencing revealed a common pathway of antibody heavy chain maturation confined to IGHV1-2*02 lineage that could pair with different light chains.Type: GrantFiled: March 23, 2012Date of Patent: April 30, 2019Assignees: Duke University, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTHInventors: John R. Mascola, Gary Nabel, Barton F. Haynes, Xueling Wu, Thomas B. Kepler, Peter Kwong
-
Patent number: 10190143Abstract: The invention relates to a method for synthesizing a selectively labeled RNA, and an apparatus for performing the method. Specific segments or discrete residues within the RNA may be selectively labeled, and different segments may include different labels.Type: GrantFiled: July 8, 2014Date of Patent: January 29, 2019Assignees: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTHInventors: Yun-Xing Wang, Yu Liu, Rui Sousa
-
Publication number: 20190011523Abstract: A system measures wireless power transfer between a transmitter and a receiver. The system includes a sensor circuit including a sensor. The sensor is configured and positioned to generate sensor data indicative of a field. The field is generated in connection with the wireless power transfer. The system further includes a processor coupled to the sensor circuit and configured to determine a power measurement based on the sensor data. The processor is further configured to determine misalignment of the transmitter or the receiver. The processor is also configured to correct an estimate of the power measurement based on the misalignment.Type: ApplicationFiled: July 9, 2018Publication date: January 10, 2019Applicant: The Regents of the University of Michigan, Univers ity of Michigan Office of Technology TransferInventors: Al-Thaddeus Avestruz, Spencer Haney, Sung Yul Chu
-
Publication number: 20180323466Abstract: The present invention demonstrates Br2-based conversion chemistry is a potential route toward rechargeable Mg-batteries. Compared with Mg-ion or Mg-air chemistries, the Mg—Br2 system features fast kinetics and good cyclability. In one embodiment, the present invention provides a rechargeable non-aqueous, dual-electrolyte scheme. In one embodiment, the anolyte consisted of Mg(TFSI)2 dissolved in a monoglyme and diglyme mixture, whereas the catholyte was composed of Mg(TFSI)2 in PYR14TFSI ionic liquid mixed with active bromine species. When Mg was used as the anode, an open circuit voltage of 3.0 V (vs. Mg2+/Mg) was measured.Type: ApplicationFiled: March 28, 2018Publication date: November 8, 2018Applicant: Boston College Office of Technology Transfer and LicensingInventors: Dunwei Wang, Xiahui Yao, Jingru Luo, Qi Dong
-
Patent number: 10087148Abstract: The present disclosure relates to certain amine derivatives of fused bicyclic heterocycles that inhibit the amine reuptake function of the biogenic amine transporters, dopamine transporter (DAT), serotonin transporter (SERT) and norepinephrine transporter (NET). Compounds of the present disclosure are potent inhibitors of the reuptake of dopamine (DA), serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE) with full or partial maximal efficacy. The compounds with partial maximal efficacy in inhibiting reuptake of all three biogenic amines are herein referred to as partial triple uptake inhibitors (PTRIs). Compounds of the present disclosure are useful for treating depression, pain and substance abuse and relapse to substance abuse and addiction to substances such as cocaine, methamphetamine, nicotine and alcohol. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: December 4, 2015Date of Patent: October 2, 2018Assignees: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTE OF HEALTH, SOUTHERN RESEARCH INSTITUTEInventors: Subramaniam Ananthan, Richard B. Rothman
-
Publication number: 20180243153Abstract: A method includes disposing a plurality of actuators about a subject, each actuator being configured to generate a respective vibration signal, each vibration signal applying a normal force to the subject, and controlling the plurality of actuators such that the respective vibration signal of each actuator of the plurality has a respective vibration characteristic. Each actuator is oriented such that the respective vibration signal propagates along a longitudinal axis of the subject for stimulation of the subject remote from the plurality of actuators.Type: ApplicationFiled: February 24, 2018Publication date: August 30, 2018Applicant: The Regents of the University of Michigan, Univers ity of Michigan Office of Technology TransferInventors: Bogdan I. Epureanu, Kevin Ward, Himanshu Saxena, Mert Egilmez
-
Patent number: 10004800Abstract: The present invention relates, in general, to HIV-1 and, in particular, to broadly neutralizing HIV-1 antibodies, and to HIV-1 immunogens and to methods of using such immunogens to induce the production of broadly neutralizing HIV-1 antibodies in a subject (e.g., a human).Type: GrantFiled: September 12, 2013Date of Patent: June 26, 2018Assignees: Duke University, Los Alamos National Security, LLC, The Trustees of The University of Pennsylvania, Trustees of Boston University, The United States of America as Represented by The Secretary of the Department of Health and Human Services National Institutes of Health Office of Technology Transfer, The Board of Trustees of the Leland Stanford Junior UniversityInventors: Barton F. Haynes, Hua-Xin Liao, Rebecca M. Lynch, Tongqing Zhou, Feng Gao, Scott Boyd, George M. Shaw, Beatrice H. Hahn, Thomas B. Kepler, Bette T. Korber, Peter Kwong, John Mascola
-
Patent number: 9867830Abstract: The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite. (2R,6R)-hydroxynorketamine The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain synthetic pain disorder (CRPD) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.Type: GrantFiled: November 2, 2016Date of Patent: January 16, 2018Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH, COOPER HEALTH SYSTEM, SRI INTERNATIONALInventors: Irving W. Wainer, Ruin Moaddel, Michel Bernier, Carlos A. Zarate, Marc C. Torjman, Michael E. Goldberg, Mary J. Tanga
-
Patent number: 9862679Abstract: Disclosed herein are bisarylmethylthioacetamides and bisarylmethylthioethylamines useful as inhibitors of monoamine transporters. The compounds are potent and/or selective inhibitors of dopamine (DA), serotonin (5-HT), and/or norepinephrine (NE) reuptake via their respective transporters, DAT, SERT and NET. Also disclosed are methods for eliciting a wake-promoting or cognitive or attention enhancing effect and for treating substance use disorders, attention deficit (hyperactivity) disorder, depressive disorders, bipolar disorder or other neuropsychiatric disorders sleep disorders or cognitive impairment using the compounds.Type: GrantFiled: March 7, 2014Date of Patent: January 9, 2018Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTHInventors: Amy Hauck Newman, Oluyomi M Okunola-Bakare, Jianjing Cao
-
Patent number: 9855225Abstract: The present invention includes methods and compositions for treating a transplant recipient by administration of a CB2 receptor agonist either alone or in combination with one or more active pharmaceutical ingredients to block the rejection of foreign tissue and prolong grafted organs, tissues and cells.Type: GrantFiled: August 17, 2012Date of Patent: January 2, 2018Assignee: TEMPLE UNIVERSITY OFFICE OF TECHNOLOGY TRANSFERInventors: Toby K. Eisenstein, Rebecca R. Hartzell, Martin W. Alder, Joseph J. Meissier
-
Patent number: 9780295Abstract: A lead-free piezoelectric ceramic material has the general chemical formula xBiCoO3-y(Bi0.5Na0.5)TiO3-z(Bi0.5K0.5)TiO3, xBiCoO3-y(Bi0.5Na0.5)TiO3-zNaN-bO3, xBiCoO3-y(Bi0.5Na0.5)TiO3-zKNbO3, xBiCoO3-yBi(Mg0.5Ti0.5)O3-z(Bi0.5Na0.5)TiO3, xBiCoO3-yBa-TiO3-z(Bi0.5Na0.5)TiO3, or xBiCoO3-yNaNbO3-zKNbO3; wherein x+y+z=1, and x, y, z?0.Type: GrantFiled: January 28, 2013Date of Patent: October 3, 2017Assignees: OREGON STATE UNIVERSITY OFFICE OF TECHNOLOGY TRANSFER, HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P.Inventors: Eric Andrew Patterson, David Cann, Peter Mardilovich
-
Patent number: 9701718Abstract: Provided are recombinant adenovirus vectors (serotype 26 and serotype 35) encoding filovirus antigens. The adenovirus vectors can be used to induce protective immune responses against filovirus infection.Type: GrantFiled: December 14, 2011Date of Patent: July 11, 2017Assignees: Janssen Vaccines & Prevention B.V., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTE OF HEALTHInventors: Nancy J. Sullivan, Gary J. Nabel, Clement Asiedu, Cheng Cheng, Maria Grazia Pau, Jaap Goudsmit